Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 17/20 | 0.68 |
| ▸ | BCHE | P06276 | 15/20 | 0.68 |
| ▸ | FAAH | O00519 | 1/20 | 0.63 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170430 | 1.00 | ACHE (0.68) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL12043578 | 0.93 | ACHE (0.65) | ACHEBCHEFAAH | |
| SCHEMBL12043574 | 0.90 | ACHE (0.71) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL18306927 | 0.90 | ACHE (0.71) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL12590098 | 0.85 | ACHE (0.69) | ACHEBCHEFAAH | |
| SCHEMBL12043576 | 0.82 | ACHE (0.65) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL12043569 | 0.82 | ACHE (0.97) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL29868287 | 0.82 | ACHE (0.97) | ACHEBCHEFAAHMARK4 | |
| Hydrochloric Acid SCHEMBL29634852 | 0.81 | ACHE (1.00) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL18138876 | 0.81 | ACHE (0.75) | ACHEBCHEFAAHMARK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-10 | — | — | US | claimed |
| US-20250319060-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2025-10-16 | — | — | US | disclosed |
| US-12239629-B2 | Methods for the prophylaxis and treatment of COVID and COVID-19 | TRAN LLOYD HUNG LOI (US) | 2025-03-04 | — | — | US | disclosed |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2023-06-08 | — | — | US | disclosed |
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | Cadila Corporate Campus (IN) | 2021-01-05 | — | — | US | disclosed |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | CADILA PHARMACEUTICALS, LTD. (IN) | 2020-03-26 | — | — | US | disclosed |
| EP-2054373-B1 | IMPROVED PROCESS FOR THE PREPARATION OF RIVASTIGMINE | ALEMBIC LTD (IN) | 2010-06-30 | — | — | EP | disclosed |
| US-7683205-B2 | Process for the preparation of Rivastigmine | ALEMBIC LIMITED (IN) | 2010-03-23 | — | — | US | disclosed |
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-20 | — | — | US | disclosed |
| US-20080045743-A1 | Process for the preparation of Rivastigmine | ALEMBIC LIMITED (IN) | 2008-02-21 | — | — | US | disclosed |
| WO-2006036928-A2 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | WAYNE STATE UNIVERSITY (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319060-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | ACE, ACE2, LPO | ACHE 13/4885BCHE 804/4885FAAH 1094/4885 |
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | ACHE, SQLE, BCHE | ACHE 1/4885BCHE 3/4885FAAH 735/4885 |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | ACHE, SQLE, BCHE | ACHE 1/4885BCHE 3/4885FAAH 735/4885 |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | APP, IAPP, PSEN1 | ACHE 18/4885BCHE 32/4885FAAH 1016/4885 |
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | MMP9, MMP10, MMP17 | ACHE 149/4885BCHE 333/4885FAAH 940/4885 |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | ACE, ACE2, LPO | ACHE 13/4885BCHE 804/4885FAAH 1094/4885 |
| US-20080045743-A1 | Process for the preparation of Rivastigmine | HNMT, HRH3, SUV39H2 | ACHE 9/4885BCHE 63/4885FAAH 442/4885 |
| US-12239629-B2 | Methods for the prophylaxis and treatment of COVID and COVID-19 | ACE, ACE2, LPO | ACHE 13/4885BCHE 804/4885FAAH 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.